Status
Conditions
Study type
Funder types
Identifiers
About
Approximately 70 million people world-wide are affected with glaucoma, of whom 6.7 million have bilateral blindness.5 Elevated intro-ocular pressure is the major modifiable risk factor in glaucoma, and reducing intraocular pressure to a consistently low level can delay disease progression and therefore, blindness.6 Topical intraocular pressure -lowering medication remains the first-line treatment for glaucoma, with surgical intervention playing a secondary role in cases suboptimally controlled with medication alone.
In this study, we plan to assess the change in tear proteins in trabeculectomy patients before and after operations. It is hoped that this study could help us gain more understanding of the possible mechanism accounting for the development of dry eye disease in glaucoma patients, which could help us develop better screening modalities and therapeutic agents for glaucoma patients at risk to prevent the development of dry eye disease.
Full description
Study Objectives and Purpose
There are two primary aims in this study:
Study Material Human Tears will be collected from patients in SNEC clinic
Study Design:
120 patients will be recruited for this study (details as described below). Schirmers I test, Tear Osmolarity, Tear Break Up Time (TBUT), Anterior segment optical coherence tomography (ASOCT) and Impression cytology will be done during the study visits. Subjective symptom and severity of dry eye disease will be assessed through Visual Analog Scale (VAS).
No. of visits:
There will be 4 visits in this study. Visit 1: Pre-trabeculectomy operation Visit 2: 6 month after trabeculectomy surgery Visit 3: 1 year after trabeculectomy surgery Visit 4: 3 years after trabeculectomy surgery
Selection and Withdrawal of Subjects Recruitment Criteria
Treatment of subjects
Study Procedures:
Fluorescein staining will be used to visualize patient eyes.
Schirmer's test will be used to measure the amount of tear production
Impression cytology will be performed to collect the superficial conjunctival cells for analysis
Tear osmolarity, Tear Break Up Time (TBUT) will be measured in all patients
a) Tear osmolarity will be measured using the osmolarity chip, 3 chips per eye
Anterior segment optical coherence tomography will be performed to assess the tear meniscus and image for any conjunctivochalasis
a) The patient will be asked to look at a target in the instrument while blinking normally. The instrument will scan the lower eyelid margin for imaging of the tear meniscus and conjunctivochalasis
Symptoms and severity of dry eye disease will be assessed through the Visual Analog Scale (VAS) system
Assessment of efficacy Outcome Measures
Target sample size 120 subjects will be enrolled in the study.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria:
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal